Find out what it's like to work at Geron and learn more about our job opportunities.

Visit Working with Us

 
 

Geron Company Overview

We are a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The discovery and early development of imetelstat, our sole product candidate, was based on our core expertise in telomerase and telomere biology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using our proprietary nucleic acid chemistry, we designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Molecular responses in essential thrombocythemia (ET) and remission responses, including reversal of bone marrow fibrosis, in myelofibrosis (MF) suggest imetelstat has disease-modifying activity by inhibiting the progenitor cells of the malignant clone for the underlying disease in a relatively selective manner.

On November 13, 2014, we entered into an exclusive collaboration and license agreement (Collaboration Agreement) with Janssen Biotech, Inc. (Janssen) to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses. Consideration under the Collaboration Agreement includes an upfront payment of $35 million which we received in December 2014, payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales.

Under the Collaboration Agreement, Janssen is responsible for the development, manufacturing and commercialization of, and seeking regulatory approval for imetelstat worldwide. Development of imetelstat will proceed under a mutually agreed clinical development plan, which includes two Phase 2 studies to be pursued initially, one in MF and one in myelodysplastic syndrome (MDS). In addition, the clinical development plan may also include additional, possible registration studies in MF and MDS, and possible exploratory Phase 2 and potential follow-on Phase 3 studies in acute myelogenous leukemia (AML).

We currently seek to acquire one or more oncology products, programs or companies to diversify our business.

Find out what it's like to work at Geron and learn more about our job opportunities.

Visit Working with Us

Close
Form content here please :)